Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BCI-540; MKC-231

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Chemical
  • Developer BrainCells; Mitsubishi Chemical; Takeda
  • Class Neuroprotectants; Nootropics; Pyrrolidinones; Quinolines; Small molecules
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Anxiety disorders; Major depressive disorder

Most Recent Events

  • 26 Jun 2012 Coluracetam is available for licensing as of 26 Jun 2012. http://www.braincellsinc.com
  • 15 May 2012 Mitsubishe Tanabe Pharma terminates a licence agreement for coluracetam (Mitsubishi Tanabe Pharma May 8 2012 pipeline)
  • 16 Jun 2010 Safety and efficacy data from a phase IIa trial in Major depressive disorder with anxiety released by BrainCells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top